María José Guillén

Author

María José Guillén

Also Known As

M GUILLEN, M José Guillén, M. J. Guillén, M. José Guillén, M.J. Guillen, M.J. Guillén, Maria Guillen, Maria J. Guillen, Maria Jose Guillen, Maria Jose Guillén

Publications

831

Citations

H-Index

Concepts

All Affiliations

PharmaMar (Spain)Universidad Autónoma de Madrid Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine Spanish National Centre for Cardiovascular Research GlaxoSmithKline (Spain)

About

María José Guillén is an author at PharmaMar (Spain) specializing in pharmacology, medicine, and biomedical engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	481
2	Engineering	5	5	173
3	Biomedical Engineering	5	5	173
4	Biochemistry	3	3	71
5	Health Sciences	1	1	68

María José Guillén

Publications

739

Citations

H-Index

Page 1

	Year	Citations
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Kris M. White, Romel Rosales, Soner Yildiz, Science MedicineViral PathogenesisImmunologyAntiviral ResponseVirology	2021	356
Tailor-made PEG coated iron oxide nanoparticles as contrast agents for long lasting magnetic resonance molecular imaging of solid cancers Ana Lázaro-Carrillo, Marco Filice, María José Guillén, Materials Science and Engineering C NanoparticlesNanomedicineEngineeringSolid CancersIron Oxide Nanoparticles	2019	68
Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation María José Alcaraz García, María José Guillén, Javier Megías, Current Pharmaceutical Design Lung InflammationImmunologyCarbon Monoxide-releasing MoleculesRedox BiologyInflammatory Arthritis	2008	49
A new potential nano-oncological therapy based on polyamino acid nanocapsules Teresa Gonzalo, Giovanna Lollo, Marcos García-Fuentes, Journal of Controlled Release NanoparticlesNanomedicineEngineeringPolymer-drug ConjugateTherapeutic Nanomaterials	2013	36
Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative Giovanna Lollo, Pablo Hervella, Pilar Calvo, International Journal of Pharmaceutics NanoparticlesNanomedicineEngineeringPlitidepsin-loaded NanocapsulesPolymer-drug Conjugate	2015	29
Lurbinectedin induces depletion of tumor-associated macrophages (TAM), an essential component of its <i>in vivo</i> synergism with gemcitabine María Virtudes Céspedes, María José Guillén, Pedro P. López‐Casas, Disease Models & Mechanisms	2016	28
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110 Juan Manuel Domı́nguez, Gema Pérez-Chacón, María José Guillén, Journal of Hematology & Oncology	2020	27
Nano-Encapsulation of Plitidepsin: In Vivo Pharmacokinetics, Biodistribution, and Efficacy in a Renal Xenograft Tumor Model Hugo Oliveira, Julie Thévenot, Élisabeth Garanger, Pharmaceutical Research NanomedicineEngineeringPolymer-drug ConjugateMedicinePharmaceutical Nanotechnology	2013	21
Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles Pau Rocas, Yolanda Fernández, Natalia García‐Aranda, Nanomedicine Nanotechnology Biology and Medicine NanomedicineDrug TargetingEngineeringPharmacokinetic ProfilePolymer-drug Conjugate	2017	19
MI130004, a Novel Antibody–Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding <i>In Vivo</i> Activity against HER2-Expressing Tumors Pablo Avilés, Juan Manuel Domı́nguez, María José Guillén, Molecular Cancer Therapeutics	2018	19

Page 1